Approval Year
| Substance Class |
Protein
Created
by
admin
on
Edited
Sat Dec 16 11:49:16 UTC 2023
by
admin
on
Sat Dec 16 11:49:16 UTC 2023
|
| Protein Sub Type | |
| Sequence Type | COMPLETE |
| Record UNII |
Z3LSI83ND8
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
Z3LSI83ND8
Created by
admin on Sat Dec 16 11:49:17 UTC 2023 , Edited by admin on Sat Dec 16 11:49:17 UTC 2023
|
PRIMARY | |||
|
P50406
Created by
admin on Sat Dec 16 11:49:17 UTC 2023 , Edited by admin on Sat Dec 16 11:49:17 UTC 2023
|
PRIMARY |
| From | To |
|---|---|
| 1_99 | 1_180 |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARTIAL AGONIST->TARGET |
|
||
|
|
INHIBITOR -> TARGET |
|
||
|
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET |
ANTAGONIST
|
||
|
ANTAGONIST->TARGET | |||
|
INHIBITOR -> TARGET |
Full antagonist SAM-760 completed phase I trials with no adverse effects at doses of up to 50 mg daily. Pfizer terminated a phase II trial after SAM-760 30 mg/day failed to produce an improvement in cognition in patients already taking a stable dose of donepezil.
|
||
|
INHIBITOR -> TARGET |
ANTAGONIST
|
||
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET |
INHIBITOR
Ki
|
||
|
INHIBITOR -> TARGET |
Phase III trials showed weak efficacy as compared to phase II trials, which may be explained by underdosing. Phase II trials evaluated the use of 90 mg daily (30 mg TID) as an adjunct to an acetylcholinesterase inhibitor. Study investigators decided to lower the dose of idalopirdine in phase III trials based on receptor occupancy analysis conducted by PET scan
|
||
|
INHIBITOR -> TARGET |
ANTAGONIST
|
||
|
INHIBITOR -> TARGET | |||
|
AGONIST -> TARGET |
|
||
|
|
INHIBITOR -> TARGET |
Ki
|
||
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET |
|
||
|
LIGAND->TARGET |
Ki
|
||
|
AGONIST -> TARGET | |||
|
WEAK INHIBITOR->TARGET |
INHIBITOR
Ki
|
||
|
AGONIST -> TARGET |
Ki
|
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| MOL_WEIGHT | CHEMICAL |
|
||||
| Molecular Formula | CHEMICAL |
|